Gilead Sciences reports positive data in remdesivir trial for Covid-19

Healthcare workers take a swab sample of a commuter-train worker during a test amid the coronavirus disease (COVID-19) outbreak, in Bogor, West Java province, Indonesia. Photo: Reuters
Gilead Sciences said on Wednesday that early results from a US government-run study showed its experimental drug to treat coronavirus helped patients recover more quickly than standard care, suggesting it could become the first effective treatment for an illness that has turned modern life inside-out.

 
The company issued a news release early Wednesday commenting on the study from the US National Institute of Allergy and Infectious Diseases without providing details of the results.

 
Anthony Fauci, the head of NIAID and the government’s top infectious-disease specialist, said at a White House meeting with President Donald Trump and Louisiana Governor John Bel Edwards that the trial showed a significant positive effect on the virus and that the results “were quite good news”.

 
Fauci called the study the “first truly high-powered randomised placebo-controlled trial” of remdesivir.

Gilead’s share price and the broader stock market have been churned in recent weeks by a series of early looks and leaks of trial data on the drug, called remdesivir. Last week, the market swooned after apparently discouraging results from a Chinese trial were accidentally posted on a World Health Organization web page. 

         
 Data confirming those more downbeat results were published in the UK medical journal The Lancet on Wednesday.

 
Gilead shares jumped as much as 7.1 per cent on Wednesday after the company’s statement. The news appeared to boost the entire US stock market as well, with the S&P 500 gaining 2.4 per cent despite data showing a deep contraction in the US economy in the first quarter of the year.

 
Remdesivir, which was originally developed to treat other novel viruses, has placed Gilead at the head of the race to develop a treatment for Covid-19. The drug, which has also been tested on Ebola, hasn’t been approved for use anywhere in the world.

A separate study released by Gilead on Wednesday said remdesivir appeared equally effective when it was given over just five days, rather than the 10-day course used in the NIAID and other trials. But the Gilead study doesn’t have a comparison group, so its findings are considered less robust.

The five-day regimen “could significantly expand the number of patients who could be treated with our current supply of remdesivir,” said Merdad Parsey, Gilead’s chief medical officer.

Taken together, the studies could signal a profound shift in the race to get the novel coronavirus under control. The availability of a treatment could allow the world to start reopening economies, as well as offer psychological relief to billions of people who have been self-isolating to hide from the virus.

 
In the most severe cases, Covid-19 can lead to respiratory failure and death. More than 1 million cases have been confirmed in the US, and over 200,000 people have died around the globe from the illness.

 
Trials Continuing

 
Multiple trials of the drug are being conducted. The NIAID trial measured how quickly patients taking it were able to be removed from supplemental oxygen therapy or were discharged from the hospital. It’s not known yet how much benefit the Gilead drug gave patients, and if it will make a meaningful difference in their care.

 
The trial, run by the National Institutes of Health, aimed to sign up about 800 patients to test the drug and give a definitive answer as to whether it can help treat the illness.

Gilead’s study of 397 patients with severe disease found those given the drug for five days did just as well as those who were treated for twice as long, and in some cases appeared to fare even better.

 
Two weeks after treatment, 65 per cent of those who got the five day dose had recovered, compared with just 54 per cent of those who received the infusion for 10 days. The death rate showed a similar trend, with 8 per cent of patients getting less drug dying, compared with 11 per cent in the 10-day group. The difference wasn’t statistically significant, which means it could have happened by chance.

 
Remdesivir will likely be approved for use in certain settings on the basis of the positive result, said Jefferies health-care strategist Jared Holz, at least until better alternatives are available.

 
“There is a massive bias to look at the data with half-glass-full approach,” he said, adding that it’s “totally fair given the current predicament.”

 
The U.S. Food and Drug Administration “has been engaged in sustained and ongoing discussions with Gilead Sciences regarding making remdesivir available to patients as quickly as possible, as appropriate,” said Michael Felberbaum, an agency spokesman, in an email.

 


Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel